Abstract
Background: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. Patients and methods: From February 2005 to April 2006, in our institute we treated 20 eligible elderly (age ≥60 years) patients with previously untreated DLBCL using a novel regimen consisting of six cycles of CHOP chemotherapy followed 6-10 weeks later by 90Y ibritumomab tiuxetan. Results: The overall response rate to the entire treatment regimen was 100%, including 95% complete remission (CR) and 5% partial remission. Four (80%) of the five patients who achieved less than a CR with CHOP improved their remission status after radioimmunotherapy. With a median follow-up of 15 months, the 2-year progression-free survival was estimated to be 75%, with a 2-year overall survival of 95%. The 90Y ibritumomab tiuxetan toxicity included grade ≥3 hematologic toxicity in 12 of 20 patients; the most common grade ≥3 toxic effects were neutropenia (12 patients) and thrombocytopenia (7 patients). Transfusions of red blood cells and/or platelets were given to one patient. Conclusion: This study has established the feasibility, tolerability, and efficacy of this regimen for elderly patients with DLBCL.
| Original language | English |
|---|---|
| Pages (from-to) | 769-773 |
| Number of pages | 5 |
| Journal | Annals of Oncology |
| Volume | 19 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2008 |
Fingerprint
Keywords
- Chemotherapy
- DLBCL
- Elderly patients
- Yttrium 90 ibritumomab tiuxetan
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients. / Zinzani, P. L.; Tani, M.; Fanti, S.; Stefoni, V.; Musuraca, G.; Castellucci, P.; Marchi, E.; Farsad, M.; Fina, M.; Pellegrini, C.; Alinari, L.; Derenzini, E.; de Vivo, A.; Bacci, F.; Pileri, S.; Baccarani, M.
In: Annals of Oncology, Vol. 19, No. 4, 04.2008, p. 769-773.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
AU - Zinzani, P. L.
AU - Tani, M.
AU - Fanti, S.
AU - Stefoni, V.
AU - Musuraca, G.
AU - Castellucci, P.
AU - Marchi, E.
AU - Farsad, M.
AU - Fina, M.
AU - Pellegrini, C.
AU - Alinari, L.
AU - Derenzini, E.
AU - de Vivo, A.
AU - Bacci, F.
AU - Pileri, S.
AU - Baccarani, M.
PY - 2008/4
Y1 - 2008/4
N2 - Background: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. Patients and methods: From February 2005 to April 2006, in our institute we treated 20 eligible elderly (age ≥60 years) patients with previously untreated DLBCL using a novel regimen consisting of six cycles of CHOP chemotherapy followed 6-10 weeks later by 90Y ibritumomab tiuxetan. Results: The overall response rate to the entire treatment regimen was 100%, including 95% complete remission (CR) and 5% partial remission. Four (80%) of the five patients who achieved less than a CR with CHOP improved their remission status after radioimmunotherapy. With a median follow-up of 15 months, the 2-year progression-free survival was estimated to be 75%, with a 2-year overall survival of 95%. The 90Y ibritumomab tiuxetan toxicity included grade ≥3 hematologic toxicity in 12 of 20 patients; the most common grade ≥3 toxic effects were neutropenia (12 patients) and thrombocytopenia (7 patients). Transfusions of red blood cells and/or platelets were given to one patient. Conclusion: This study has established the feasibility, tolerability, and efficacy of this regimen for elderly patients with DLBCL.
AB - Background: A prospective, single-arm, open-label, nonrandomized phase II combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) plus radioimmunotherapy trial was conducted to evaluate the efficacy and safety in untreated elderly diffuse large B-cell lymphoma (DLBCL) patients. Patients and methods: From February 2005 to April 2006, in our institute we treated 20 eligible elderly (age ≥60 years) patients with previously untreated DLBCL using a novel regimen consisting of six cycles of CHOP chemotherapy followed 6-10 weeks later by 90Y ibritumomab tiuxetan. Results: The overall response rate to the entire treatment regimen was 100%, including 95% complete remission (CR) and 5% partial remission. Four (80%) of the five patients who achieved less than a CR with CHOP improved their remission status after radioimmunotherapy. With a median follow-up of 15 months, the 2-year progression-free survival was estimated to be 75%, with a 2-year overall survival of 95%. The 90Y ibritumomab tiuxetan toxicity included grade ≥3 hematologic toxicity in 12 of 20 patients; the most common grade ≥3 toxic effects were neutropenia (12 patients) and thrombocytopenia (7 patients). Transfusions of red blood cells and/or platelets were given to one patient. Conclusion: This study has established the feasibility, tolerability, and efficacy of this regimen for elderly patients with DLBCL.
KW - Chemotherapy
KW - DLBCL
KW - Elderly patients
KW - Yttrium 90 ibritumomab tiuxetan
UR - http://www.scopus.com/inward/record.url?scp=41549144308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=41549144308&partnerID=8YFLogxK
U2 - 10.1093/annonc/mdm560
DO - 10.1093/annonc/mdm560
M3 - Article
C2 - 18303033
AN - SCOPUS:41549144308
VL - 19
SP - 769
EP - 773
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 4
ER -